$9.60 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Evolus

Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.

Stock Analysis

last close $9.6
1-mo return -26%
3-mo return -20.3%
avg daily vol. 637.55T
52-week high 14.34
52-week low 5.06
market cap. $539M
forward pe -
annual div. -
roe -102.7%
ltg forecast -
dividend yield -
annual rev. $132M
inst own. 45.9%

Subscribe now for daily local and international financial news